Logo image of CGEM

CULLINAN THERAPEUTICS INC (CGEM) Stock Fundamental Analysis

NASDAQ:CGEM - Nasdaq - US2300311063 - Common Stock - Currency: USD

9.03  -0.12 (-1.31%)

After market: 9.03 0 (0%)

Fundamental Rating

3

Taking everything into account, CGEM scores 3 out of 10 in our fundamental rating. CGEM was compared to 571 industry peers in the Biotechnology industry. CGEM has a great financial health rating, but its profitability evaluates not so good. CGEM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CGEM has reported negative net income.
In the past year CGEM has reported a negative cash flow from operations.
CGEM had negative earnings in 4 of the past 5 years.
In the past 5 years CGEM always reported negative operating cash flow.
CGEM Yearly Net Income VS EBIT VS OCF VS FCFCGEM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -21.97%, CGEM is in the better half of the industry, outperforming 76.02% of the companies in the same industry.
CGEM has a Return On Equity of -22.86%. This is amongst the best in the industry. CGEM outperforms 83.48% of its industry peers.
Industry RankSector Rank
ROA -21.97%
ROE -22.86%
ROIC N/A
ROA(3y)-8.94%
ROA(5y)-14.3%
ROE(3y)-9.47%
ROE(5y)-15.15%
ROIC(3y)N/A
ROIC(5y)N/A
CGEM Yearly ROA, ROE, ROICCGEM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 20 -20 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CGEM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGEM Yearly Profit, Operating, Gross MarginsCGEM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -100 -200 -300

More info and screens

9

2. Health

2.1 Basic Checks

The number of shares outstanding for CGEM has been reduced compared to 1 year ago.
CGEM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CGEM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGEM Yearly Shares OutstandingCGEM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
CGEM Yearly Total Debt VS Total AssetsCGEM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

CGEM has an Altman-Z score of 12.00. This indicates that CGEM is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 12.00, CGEM belongs to the top of the industry, outperforming 88.28% of the companies in the same industry.
There is no outstanding debt for CGEM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12
ROIC/WACCN/A
WACCN/A
CGEM Yearly LT Debt VS Equity VS FCFCGEM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 24.46 indicates that CGEM has no problem at all paying its short term obligations.
CGEM's Current ratio of 24.46 is amongst the best of the industry. CGEM outperforms 96.27% of its industry peers.
CGEM has a Quick Ratio of 24.46. This indicates that CGEM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 24.46, CGEM belongs to the top of the industry, outperforming 96.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 24.46
Quick Ratio 24.46
CGEM Yearly Current Assets VS Current LiabilitesCGEM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.06% over the past year.
EPS 1Y (TTM)24.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CGEM will show a small growth in Earnings Per Share. The EPS will grow by 4.07% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15.57%
EPS Next 2Y7.07%
EPS Next 3Y5.42%
EPS Next 5Y4.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CGEM Yearly Revenue VS EstimatesCGEM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
CGEM Yearly EPS VS EstimatesCGEM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CGEM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CGEM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGEM Price Earnings VS Forward Price EarningsCGEM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGEM Per share dataCGEM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.07%
EPS Next 3Y5.42%

More info and screens

0

5. Dividend

5.1 Amount

CGEM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CULLINAN THERAPEUTICS INC

NASDAQ:CGEM (2/21/2025, 8:08:00 PM)

After market: 9.03 0 (0%)

9.03

-0.12 (-1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-06 2025-03-06/amc
Inst Owners110.57%
Inst Owner Change2.4%
Ins Owners0.93%
Ins Owner Change-0.23%
Market Cap525.82M
Analysts87.5
Price Target33.66 (272.76%)
Short Float %16.55%
Short Ratio16.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.36%
Min EPS beat(2)-1.34%
Max EPS beat(2)16.07%
EPS beat(4)3
Avg EPS beat(4)18.62%
Min EPS beat(4)-1.34%
Max EPS beat(4)44.94%
EPS beat(8)6
Avg EPS beat(8)8.22%
EPS beat(12)8
Avg EPS beat(12)6.88%
EPS beat(16)10
Avg EPS beat(16)-38.96%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.87%
EPS NQ rev (1m)6.07%
EPS NQ rev (3m)9.02%
EPS NY rev (1m)1.74%
EPS NY rev (3m)5.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.84
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-2.84
EYN/A
EPS(NY)-3.15
Fwd EYN/A
FCF(TTM)-2.18
FCFYN/A
OCF(TTM)-2.18
OCFYN/A
SpS0
BVpS10.78
TBVpS10.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.97%
ROE -22.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-8.94%
ROA(5y)-14.3%
ROE(3y)-9.47%
ROE(5y)-15.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.46
Quick Ratio 24.46
Altman-Z 12
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)440.88%
Cap/Depr(5y)273.58%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.18%
EPS Next Y15.57%
EPS Next 2Y7.07%
EPS Next 3Y5.42%
EPS Next 5Y4.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.91%
EBIT Next 3Y-2.08%
EBIT Next 5YN/A
FCF growth 1Y-8.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.53%
OCF growth 3YN/A
OCF growth 5YN/A